In NPM1mut-AML, 20% of patients will have TET2 mutation and this carries poor outcome in high-risk cytogenetics, or with NPM1mut with FLT3-ITD and isolated TET2 mutation with NPM1wt (i.e., TET2+/ NPM1−) [34]. This evidence concerns the gene FLT3 and acute myeloid leukemia.